Treats Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive. ANDA 207105, held by Alkem Labs Ltd. Aripiprazole.
As of Nov 16, 2026, ANDA 207105 (Aripiprazole), held by Alkem Labs Ltd, was first approved by FDA on Feb 21, 2019, with 3 approved supplements and 0 published complete response letters.
Aripiprazole tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole tablets are an atypical antipsychotic. Aripiprazole tablets are indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 21, 2019 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
| Jul 17, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 17, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 17, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 21, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters